Ann: Comparative Analysis Indicates Benefits from OncoSil, page-4

These are promising results, especially point 1, which shows patients receiving the combination therapy had an average survival time that was about 32% greater than those receiving chemotherapy alone.

The study investigates the effectiveness of combining standard chemotherapy with endoscopic ultrasound (EUS)-guided phosphorus-32 (^32P) microparticle intra-tumoral implantation in patients with locally advanced pancreatic cancer (LAPC). The researchers aimed to compare this combination therapy with standard chemotherapy alone using a propensity-score weighted analysis (PSWA) to reduce selection bias.

Key Findings:

1. Overall Survival Improvement:

   • The combination therapy group had a significantly longer restricted mean survival time (RMST) within 24 months after chemotherapy initiation. Specifically, an estimated 112 days longer than the chemotherapy-only group (459 days vs. 347 days).

2. Enhanced Local Progression-Free Time:

   • Patients receiving the combined treatment experienced an extended local progression-free time by an estimated 112 days compared to those on standard chemotherapy alone.

3. Higher Probability of Tumor Downstaging:

   • There was a 22.3% higher probability of tumor downstaging in the combination therapy group, suggesting better disease control.

4. Increased Tumor Vascularity:

   • Contrast-enhanced EUS (CE-EUS) assessments showed a significant increase in intra-tumoral vascularity at 4 and 12 weeks post-^32P implantation. This suggests that the combined treatment may enhance the delivery of chemotherapy agents to the tumor by improving microvascular flow.